Bionik Laboratories to Attend the 2017 American Occupational Therapy Association (AOTA) Conference and Centennial Celebration
TORONTO and BOSTON, March 29, 2017 (GLOBE NEWSWIRE) -- Bionik Laboratories Corp. (OTCQX:BNKL) (“Bionik” or the "Company"), a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home, announced today the company will be attending the 2017 AOTA Conference and Centennial Celebration from March 30 through April 2, 2017, at the Pennsylvania Convention Center, Philadelphia, Pennsylvania.
During this convention the Company will be showcasing its InMotion robotic products, the most studied robots for the effective treatment of the neurologically impaired, with over 200 peer-reviewed and published articles from some of the most respected research institutions in the world. Attendees are invited to stop by booth 1415 to meet with members of the Bionik team and request a free demonstration of the Company’s evidence-based neuro recovery robotic products.
“We are very excited to attend this important professional conference and honored to be participating in their centennial celebration, which is an incredible achievement,” stated Peter Bloch, Bionik CEO and chairman of the board. “Bionik is looking forward to the opportunity to meet with all members of the association and to showcase our InMotion robotic solutions for the neurologically impaired patient population. Speaking directly with industry leaders is critically important to Bionik as we continue to demonstrate our value and partner capabilities to all stakeholders within the healthcare community and across the continuum of care: patients, their families, care providers and payers.”
About AOTA Conference & Expo 2017
The American Occupational Therapy Association Annual Conference & Expo is the place where certified occupational therapists gather each year to further their educational commitment to the profession. The Expo Hall is the place to make positive and lasting connections by interacting face-to-face with hundreds of exhibitors who help fuel the growth of the profession and assist the profession in improving the lives of millions of people. This four-day event is being organized by the American Occupational Therapy Association (AOTA). The venue is the Pennsylvania Convention Center, which is located in Philadelphia, Pennsylvania. The event will take place March 30 through April 2, 2017. AOTA Conference & Expo 2017 exhibitors will showcase a wide range of products and services related to the medical sector, such as assessment and evaluation tools; therapeutic devices and equipment; books and practice guides; pediatric, physical rehabilitation and geriatric resources; and technology solutions and software. The approximate number of exhibitors at this event is over 350, and over 7,000 people are expected to attend.
About Bionik Laboratories
Bionik Laboratories (OTCQX:BNKL) is a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home. The Company has a portfolio of products for both upper and lower extremity impairments, including three products on the market and four products in varying stages of development. The InMotion Systems — the InMotion ARM™, InMotion Wrist™, InMotion Hand™ and InMotion AnkleBot™ — are designed to provide intelligent, patient-adaptive therapy in a manner that has been clinically verified to maximize neuro-recovery. Bionik is also developing a lower-body exoskeleton, ARKE™, designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate through walking. ARKE is designed to continually adapt to a patient’s ability and provide real-time feedback to the physiotherapist.
For more information, please visit www.bioniklabs.com and connect with us on Twitter, LinkedIn and Facebook.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons and other robotic rehabilitation products, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii), above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.
Contact: Investor Relations Bionik Laboratories firstname.lastname@example.org (800) 906-6498
Released March 29, 2017